See more : AUO Corporation (2409.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Genfit S.A. (GNFT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Genfit S.A., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Infinite Group, Inc. (IMCIW) Income Statement Analysis – Financial Results
- Powell Industries, Inc. (POWL) Income Statement Analysis – Financial Results
- TENPOS HOLDINGS Co.,Ltd. (2751.T) Income Statement Analysis – Financial Results
- Mortech Corporation (7419.TWO) Income Statement Analysis – Financial Results
- Shinsei Bank, Limited (SKLKF) Income Statement Analysis – Financial Results
Genfit S.A. (GNFT)
About Genfit S.A.
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 28.57M | 20.20M | 80.07M | 765.00K | 30.84M | 69.00K | 118.00K | 284.00K | 527.00K | 1.61M | 1.90M | 1.67M | 2.36M | 3.76M | 5.81M | 8.76M | 9.48M | 10.05M | 12.77M |
| Cost of Revenue | 341.00K | 248.00K | 161.00K | 202.00K | 177.00K | 1.85M | 2.23M | 1.99M | 1.93M | 1.40M | 1.29M | 1.20M | 1.41M | 1.37M | 1.61M | 1.74M | 2.01M | 1.69M | 1.32M |
| Gross Profit | 28.22M | 19.95M | 79.91M | 563.00K | 30.66M | -1.79M | -2.11M | -1.70M | -1.40M | 210.10K | 606.40K | 477.20K | 949.30K | 2.39M | 4.21M | 7.02M | 7.47M | 8.37M | 11.46M |
| Gross Profit Ratio | 98.81% | 98.77% | 99.80% | 73.59% | 99.43% | -2,586.96% | -1,788.98% | -598.94% | -266.41% | 13.01% | 31.93% | 28.54% | 40.21% | 63.57% | 72.37% | 80.10% | 78.84% | 83.23% | 89.68% |
| Research & Development | 46.71M | 35.82M | 35.17M | 59.10M | 66.17M | 47.66M | 35.10M | 19.19M | 5.39M | 9.02M | 5.16M | 4.29M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 8.04M | 16.41M | 16.15M | 14.27M | 17.27M | 13.63M | 13.41M | 11.66M | 9.13M | 9.37M | 7.38M | 6.45M | 6.02M | 6.91M | 0.00 | 0.00 | 6.20M | 4.81M | 4.71M |
| Selling & Marketing | 0.00 | 992.00K | 1.54M | 11.22M | 13.71M | 717.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.04M | 17.40M | 17.69M | 25.49M | 30.97M | 13.63M | 13.41M | 11.66M | 9.13M | 9.37M | 7.38M | 6.45M | 6.02M | 6.91M | 0.00 | 0.00 | 6.20M | 4.81M | 4.71M |
| Other Expenses | 53.00K | -5.72M | -4.75M | -6.23M | -8.47M | 6.41M | 6.08M | 1.61M | 1.75M | 100.00 | -1.51M | -100.00 | 2.68M | 3.14M | 10.69M | 12.20M | 7.27M | 4.11M | 5.07M |
| Operating Expenses | 54.80M | 47.50M | 48.11M | 78.35M | 88.67M | 67.70M | 54.58M | 32.46M | 16.27M | 17.48M | 11.02M | 8.19M | 8.70M | 10.04M | 10.69M | 12.20M | 13.47M | 8.92M | 9.78M |
| Cost & Expenses | 55.15M | 47.50M | 48.11M | 78.35M | 88.67M | 69.55M | 56.81M | 34.44M | 18.20M | 18.88M | 12.32M | 9.39M | 10.11M | 11.41M | 12.29M | 13.94M | 15.47M | 10.61M | 11.10M |
| Interest Income | 1.71M | 8.21M | 44.78M | 6.54M | 5.22M | 202.00K | 389.00K | 316.00K | 437.00K | 329.00K | 169.20K | 201.40K | 322.80K | 205.70K | 300.90K | 596.00K | 768.90K | 399.70K | 53.40K |
| Interest Expense | 4.62M | 4.76M | 7.12M | 25.30M | 13.11M | 10.98M | 1.39M | 110.00K | 0.00 | 93.70K | 103.10K | 238.40K | 372.80K | 391.40K | 449.10K | 205.20K | 390.80K | 308.80K | 332.90K |
| Depreciation & Amortization | 1.65M | 1.83M | 2.74M | 4.75M | 5.25M | 1.44M | 1.53M | 799.00K | 327.00K | 292.10K | 465.50K | 556.30K | 788.80K | 919.60K | 1.06M | 1.00M | 943.90K | 537.70K | 874.40K |
| EBITDA | -22.24M | -23.60M | 34.91M | -91.14M | -51.02M | -68.08M | -55.76M | -33.53M | -17.35M | -16.98M | -9.95M | -6.77M | -6.64M | -6.53M | -5.09M | -3.41M | -4.07M | 930.30K | 2.60M |
| EBITDA Ratio | -77.84% | -85.45% | 99.26% | -8,821.70% | -153.07% | -97,182.61% | -46,264.41% | -11,550.70% | -3,146.30% | -1,029.08% | -509.17% | -405.08% | -281.18% | -173.79% | -88.67% | -40.07% | -43.19% | 1.16% | 20.38% |
| Operating Income | -26.58M | -27.55M | 76.74M | -77.79M | -57.83M | -69.48M | -56.70M | -34.16M | -17.68M | -17.26M | -10.51M | -7.72M | -7.75M | -7.66M | -6.47M | -5.17M | -5.99M | -553.30K | 1.68M |
| Operating Income Ratio | -93.05% | -136.41% | 95.84% | -10,168.76% | -187.53% | -100,701.45% | -48,046.61% | -12,027.46% | -3,354.08% | -1,069.04% | -553.56% | -461.39% | -328.32% | -203.82% | -111.40% | -59.06% | -63.21% | -5.50% | 13.12% |
| Total Other Income/Expenses | -1.93M | 3.45M | -7.26M | -18.75M | -7.89M | -10.39M | -2.45M | 526.00K | 541.00K | 234.00K | 179.60K | -13.60K | -50.00K | -185.70K | -177.50K | 559.20K | 611.00K | 223.60K | 33.40K |
| Income Before Tax | -28.51M | -23.84M | 69.47M | -101.65M | -65.72M | -79.88M | -58.22M | -33.63M | -17.14M | -17.03M | -10.33M | -7.73M | -7.80M | -7.84M | -6.65M | -4.71M | -5.38M | -329.70K | 1.71M |
| Income Before Tax Ratio | -99.82% | -118.03% | 86.77% | -13,287.45% | -213.11% | -115,760.87% | -49,338.14% | -11,841.55% | -3,251.42% | -1,054.57% | -544.10% | -462.21% | -330.44% | -208.76% | -114.46% | -53.79% | -56.76% | -3.28% | 13.38% |
| Income Tax Expense | 380.00K | -116.00K | 2.22M | -428.00K | -576.00K | -354.00K | 384.00K | 35.00K | 227.00K | 400.00 | 2.32M | -2.32M | 1.88M | 1.54M | 721.50K | -751.40K | -2.58M | -665.40K | 74.40K |
| Net Income | -28.89M | -23.72M | 67.26M | -101.22M | -65.15M | -79.52M | -58.60M | -33.67M | -17.14M | -17.03M | -12.65M | -5.41M | -9.68M | -9.38M | -7.37M | -3.96M | -2.80M | 327.70K | 1.77M |
| Net Income Ratio | -101.15% | -117.45% | 84.00% | -13,231.50% | -211.24% | -115,247.83% | -49,664.41% | -11,854.58% | -3,251.42% | -1,054.60% | -666.15% | -323.60% | -410.09% | -249.65% | -126.87% | -45.21% | -29.55% | 3.26% | 13.88% |
| EPS | -0.58 | -0.48 | 1.50 | -2.60 | -1.76 | -2.55 | -1.88 | -1.28 | -0.69 | -0.76 | -0.65 | -0.35 | -0.75 | -0.78 | -0.63 | -0.34 | -0.24 | 0.03 | 0.15 |
| EPS Diluted | -0.58 | -0.48 | 1.21 | -2.60 | -1.76 | -2.55 | -1.88 | -1.25 | -0.69 | -0.74 | -0.63 | -0.35 | -0.75 | -0.78 | -0.63 | -0.34 | -0.24 | 0.03 | 0.15 |
| Weighted Avg Shares Out | 49.70M | 49.67M | 44.74M | 38.86M | 36.99M | 31.17M | 31.16M | 26.35M | 24.70M | 22.29M | 19.41M | 15.32M | 12.88M | 11.97M | 11.62M | 11.62M | 11.62M | 11.62M | 11.62M |
| Weighted Avg Shares Out (Dil) | 49.70M | 49.67M | 55.61M | 38.86M | 36.99M | 31.17M | 31.17M | 26.85M | 24.70M | 22.98M | 20.01M | 15.32M | 12.88M | 11.97M | 11.62M | 11.62M | 11.62M | 11.62M | 11.62M |
GENFIT SA (GNFT) CEO Pascal Prigent on Q2 2020 Results - Earnings Call Transcript
GENFIT SA (NASDAQ:GNFT) Q2 2020 Results Conference Call September 30, 2020 04:30 PM ET Company Participants Stefanie Magner - Deputy Director, Legal Affairs Pascal Prigent - CEO Dean Hum - Chief Scientific Officer and COO Conference Call Participants Thomas Smith...
Genfit (GNFT) Presents At Digital International Liver Congress 2020
The following slide deck was published by Genfit SA in conjunction with this event.
Viking Therapeutics: Another Year In Review
Recently announced Q2'20 financial results and provided key updates on development timelines. Filed IND for VK0214 in X-ALD.
Theratechnologies NASH Data And Other News: The Good, Bad And Ugly Of Biopharma
Theratechnologies announces positive report for tesamorelin in NASH. Blueprint reports positive EU response for GIST treatment.
XBiotech Breakthrough, And Other News: The Good, Bad And Ugly Of Biopharma
XBiotech makes a crucial breakthrough in True Human antibodies development. Novocure begins pivotal Phase 2 trial for brain cancer therapy.
Genfit abandons late-stage trial of NASH drug elafibranor -
France’s Genfit has said its elafibranor drug as a treatment for non-alcoholic steatohepatitis (NASH) was unable to improve
Intercept Pharmaceuticals: Regulatory Snub Unsettles Liver Therapy Front-Runner
The FDA decision has wiped out more than a third of Intercept’s market cap. Yet, the company remains the front runner in the NASH space. The current trading mul
Genfit : L'américain Intercept, rival de Genfit, se prend à son tour les pieds dans le tapis
(BFM Bourse) - L'agence américaine du médicament a refusé d'homologuer l'Ocaliva (acide obéticholique) d'Intercept pour le traitement de la fibrose du foie …
Source: https://incomestatements.info
Category: Stock Reports